Trichomonas vaginalis: The World's Most Common Non-Viral Sexually Transmitted Infection

Trichomonas vaginalis infects an estimated 156 million people worldwide each year — more than gonorrhea and chlamydia combined. It is often asymptomatic, especially in men, but causes vaginal discharge, itching, and burning in women and is associated with increased HIV transmission risk and adverse pregnancy outcomes. Despite its enormous global burden, it remains among the most underdiagnosed sexually transmitted infections.

Table of Contents

1. What T. vaginalis Is
2. Why It Is So Widespread
3. Symptoms in Women
4. Symptoms (or Lack Thereof) in Men
5. Complications — HIV Risk and Preterm Birth
6. Diagnosis
7. Treatment (Metronidazole, Tinidazole)
8. Partner Treatment and Reinfection
9. Key Research Papers
10. Featured Videos

1. What T. vaginalis Is

Trichomonas vaginalis is a single-celled flagellated protozoan parasite. It belongs to the phylum Parabasalia and is the only Trichomonas species pathogenic to humans. Unlike most protozoan pathogens, it has no cyst stage: it exists only as an actively motile trophozoite and cannot survive outside the human body for more than a few hours. This means transmission is almost exclusively sexual — direct mucous membrane contact during sex.

The organism is roughly ovoid to pear-shaped, 10–20 μm in length, and propels itself with four anterior flagella plus an undulating membrane. Under the microscope, the characteristic tumbling, jerky motility of live organisms in vaginal discharge is diagnostic. T. vaginalis infects the squamocolumnar epithelium of the lower urogenital tract — the vagina and cervix in women, the urethra and prostate in men. It attaches to epithelial cells, damages them directly through contact-dependent cytotoxicity, and triggers an inflammatory response.

The World Health Organization estimates approximately 156 million new cases occur globally each year, making trichomoniasis the most common curable sexually transmitted infection worldwide. Prevalence is highest in sub-Saharan Africa and in lower-income populations globally. In the United States, an estimated 2.6–3.7 million people are infected at any one time, making it far more prevalent than gonorrhea or chlamydia.

2. Why It Is So Widespread

Several biological and social factors make T. vaginalis extraordinarily common:

• High asymptomatic rate: The majority of infected men and many infected women have no symptoms. Asymptomatic individuals do not seek diagnosis or treatment and remain unaware they are transmitting the infection.
• No lasting immunity: Unlike viral infections, recovery from trichomoniasis does not protect against reinfection. Repeated infections are common.
• Survival on surfaces: Although T. vaginalis cannot form cysts, it can survive on moist surfaces (wet towels, sex toys) for several hours, allowing very rare non-sexual transmission through shared objects, though this route is much less important than sexual contact.
• Under-testing: Trichomoniasis is not routinely screened for in most clinical settings — standard STI panels for chlamydia and gonorrhea often do not include T. vaginalis unless specifically ordered. This contributes to ongoing transmission by infected, undiagnosed individuals.
• Social determinants: Poverty, limited healthcare access, and high partner concurrency rates in affected communities amplify transmission at a population level.

3. Symptoms in Women

Approximately 70% of infected women eventually develop symptoms, though the onset can be delayed weeks to months after initial infection. Classic symptoms include:

• Vaginal discharge: The characteristic discharge of trichomoniasis is described as thin, frothy (bubbly), yellow-green, and malodorous. In practice, the discharge is highly variable — it may be thin or thick, white, gray, or yellow-green. Only a minority of cases have the "classic" frothy yellow-green appearance.
• Vaginal itching and burning: The inflammatory response to T. vaginalis infection causes significant vulvar and vaginal irritation.
• Dyspareunia: Pain during sexual intercourse due to vaginal inflammation.
• Dysuria: Burning or pain during urination, caused by urethral involvement.

On pelvic examination, the vaginal walls may appear erythematous (red) and edematous. The cervix may show punctate hemorrhages — the “strawberry cervix” or colpitis macularis — visible in a minority of cases but highly specific for trichomoniasis when present. Vaginal pH is typically elevated above 4.5.

4. Symptoms (or Lack Thereof) in Men

Men are significantly less likely to have symptoms than women. The majority of infected men are completely asymptomatic. When symptoms do occur, they include:

• Urethral discharge (typically mild, mucoid)
• Dysuria (burning during urination)
• Urethral irritation or pruritis

The urethra is the primary site of infection in men, but T. vaginalis can also infect the epididymis, prostate, and seminal vesicles. Prostatitis due to T. vaginalis has been described and may contribute to chronic pelvic symptoms. Importantly, asymptomatic infected men serve as silent reservoirs, maintaining transmission to female partners who then develop symptomatic infection. The pattern in which a woman repeatedly becomes symptomatic after treatment while her male partner goes untested and untreated is a common cause of persistent or recurrent trichomoniasis in women.

5. Complications — HIV Risk and Preterm Birth

Beyond its immediate symptoms, T. vaginalis infection has important consequences for HIV transmission and pregnancy:

• Increased HIV acquisition risk: Trichomoniasis approximately doubles the risk of acquiring HIV in both men and women. Multiple mechanisms contribute. The genital inflammation and epithelial disruption caused by T. vaginalis create a portal of entry for HIV. The immune response recruits CD4+ T cells and macrophages — the very cells HIV targets — to the genital mucosa, concentrating susceptible target cells at the site of potential HIV exposure. Studies in sub-Saharan Africa have demonstrated that trichomoniasis is associated with significantly increased HIV shedding in the genital tract of HIV-positive women, increasing transmissibility to partners.
• Adverse pregnancy outcomes: Trichomoniasis during pregnancy is associated with preterm birth, premature rupture of membranes, and low birth weight. The mechanisms are believed to involve ascending infection and local production of inflammatory cytokines (prostaglandins and interleukins) that trigger early labor. Treatment during pregnancy is recommended, though data on whether treatment actually reduces preterm birth rates have been mixed.
• Possible link to prostate cancer: Some studies have found associations between T. vaginalis seropositivity and an increased risk of aggressive prostate cancer in men, possibly mediated by chronic prostatic inflammation, though this relationship is not definitively established.

6. Diagnosis

Diagnosis of trichomoniasis requires laboratory testing; clinical diagnosis based on symptoms and signs alone is unreliable due to variable presentation. Options include:

• Nucleic acid amplification tests (NAATs): The most sensitive and specific diagnostic method, with sensitivity above 95%. NAATs detect T. vaginalis DNA or RNA in vaginal or endocervical swabs (in women) or urine or urethral swabs (in men). They are now available on FDA-cleared platforms and are the recommended first-line test for high-risk populations.
• Wet mount microscopy: Historically the most widely used test, examining fresh vaginal discharge under a light microscope for the characteristic motile trichomonads. Sensitivity is only 50–70% even under ideal conditions, and sensitivity falls rapidly as the specimen ages. A negative wet mount does not rule out infection.
• Point-of-care antigen tests: Several rapid antigen tests (e.g., OSOM Trichomonas Rapid Test) detect T. vaginalis antigen with sensitivity of approximately 82–95% and specificity over 97% in women; they provide results within minutes at the point of care. Less reliable in men.
• Culture: More sensitive than wet mount but takes 3–7 days; used primarily in research settings or when other tests are unavailable.
• Pap smear: Can incidentally detect T. vaginalis but has poor sensitivity (<60%) and significant false-positive rate; not recommended as a primary diagnostic method.

7. Treatment (Metronidazole, Tinidazole)

Trichomoniasis is curable. The recommended treatments are nitroimidazole antibiotics:

• Metronidazole: The standard first-line treatment. For women, CDC guidelines recommend 500 mg orally twice daily for 7 days (preferred over single-dose for higher cure rates). For men, a single oral dose of 2 g is also effective. Metronidazole penetrates into all tissues where the organism resides and achieves high concentrations in the genital tract.
• Tinidazole: An alternative nitroimidazole with a longer half-life, given as a single 2 g oral dose. Preferred by some clinicians for its convenience and because some strains resistant to metronidazole remain susceptible to tinidazole.

Both drugs work by being reduced inside anaerobic cells (and in anaerobic organisms like T. vaginalis) to toxic intermediates that damage DNA. They should not be taken with alcohol (Antabuse-like reaction). Patients should be advised to abstain from sex until both they and their partner(s) have completed treatment and are symptom-free.

Metronidazole resistance is an emerging concern. Low-level resistance is found in approximately 4–10% of T. vaginalis isolates; higher-level resistance is less common. Treatment-refractory cases may require higher doses of metronidazole, extended courses, or tinidazole.

8. Partner Treatment and Reinfection

Reinfection after successful treatment is very common and is the primary reason trichomoniasis persists in many people. Unless all current sex partners are simultaneously diagnosed and treated, reinfection from the untreated partner is nearly certain.

Current CDC guidelines recommend partner treatment as a core component of trichomoniasis management. Expedited partner therapy (EPT) — providing the patient with medication or a prescription for their partner(s) without the partner first seeing a clinician — is legally permissible and recommended in many US states as an effective strategy for treating partners who may not independently seek care.

Patients treated for trichomoniasis have a high reinfection rate at 3 months — studies report 17% reinfection in women by 3 months post-treatment. The CDC recommends rescreening at 3 months after treatment for all women diagnosed with trichomoniasis. Frequent rescreening is particularly important in high-prevalence populations.

Key Research Papers

Landmark studies and reviews on Trichomonas vaginalis epidemiology, complications, and treatment.

1. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1–187.
2. Kissinger P. Trichomonas vaginalis: A Review of Epidemiologic, Clinical and Treatment Issues. BMC Infectious Diseases. 2015;15:307. [PubMed PMID 25903457]
3. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis Increases the Risk of HIV-1 Acquisition. Journal of Infectious Diseases. 2007;195(5):698–702. [PubMed PMID 17330795]
4. Schwebke JR, Burgess D. Trichomoniasis. Clinical Microbiology Reviews. 2004;17(4):794–803. [PubMed PMID 14557293]
5. Muzny CA, Schwebke JR. The Clinical Spectrum of Trichomonas vaginalis Infection and Challenges to Management. Sexually Transmitted Infections. 2013;89(6):423–425. [PubMed PMID 28687519]

Live PubMed Searches

1. Trichomonas vaginalis epidemiology
2. Trichomoniasis HIV transmission
3. Trichomoniasis pregnancy preterm birth
4. Metronidazole tinidazole treatment
5. T. vaginalis NAAT diagnosis
6. Trichomoniasis reinfection partner treatment

Back to Table of Contents

Connections

• Symptoms Overview
• Vaginal & Urethral Symptoms
• Complications & Pregnancy Risks
• Diagnosis: Wet Mount & NAAT
• Treatment Overview
• Metronidazole & Tinidazole
• Partner Treatment & Reinfection
• Prevention & Screening
• All Parasites
• Giardia
• Toxoplasma
• Reproductive Medicine
• Infectious Disease
• All Conditions

Back to Table of Contents

Featured Videos